- $1.67bn
- $1.43bn
- $62.90m
Brief: Nuvation Bio Q2 EPS USD -0.17
Nuvation Bio Inc expected to post a loss of 17 cents a share - Earnings Preview
Focus: US pharma bets big on China to snap up potential blockbuster drugs
US FDA approves Nuvation Bio's lung cancer therapy (updated)
US FDA approves Nuvation Bio's lung cancer therapy
Brief: FDA Approves Taletrectinib For ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Nuvation Bio Q1 EPS USD -0.16
Nuvation Bio Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Nuvation Bio Enters Supply Agreement With Asymchem For Taletrectinib
Brief: Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
U.S. RESEARCH ROUNDUP-Abbvie, Dick's Sporting, Oracle
Brief: Nuvation Bio Inc Files For Mixed Shelf, Size Not Disclosed
Nuvation Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Nuvation Bio Q4 EPS USD -0.15
Brief: Nuvation Bio Enters Supply Agreement With Asymchem Laboratories
Brief: Nuvation Bio Secures Up To $250 Million In Non-Dilutive Financings From Sagard Healthcare Partners
Brief: Nuvation Bio Receives Approval From China's National Medical Products Administration For Taletrectinib For Patients With Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc reports results for the quarter ended in September 30 - Earnings Summary